2-[1,1-bis(trifluoromethyl)-2,2,2-trifluoroethoxy]ethyl amine | 205117-38-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[1,1-bis(trifluoromethyl)-2,2,2-trifluoroethoxy]ethyl amine
• 英文别名: 2-(nonafluoro-tert-butoxy)ethylamine；2-(Nonafluoro tert-butyloxy)ethylamine；2-[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxyethanamine
• CAS: 205117-38-0
• 化学式: C₆H₆F₉NO
• 分子量: 279.105
• InChiKey: UHWPPNMWUSFNQA-UHFFFAOYSA-N

物化性质

• 沸点：
  137.0±35.0 °C(Predicted)
• 密度：
  1.493±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-[1,1-bis(trifluoromethyl)-2,2,2-trifluoroethoxy]ethyl amine 、 N-苄氧羰基-L-丝氨酸苯醚 在 偶氮二甲酸二苄酯 、 三苯基膦 、 palladium 10% on activated carbon 、 氢气 作用下， 以 二甲基亚砜 、 甲醇 为溶剂， 反应 8.0h， 以56%的产率得到3-{N-[2-(nonafluoro-tert-butoxy)ethyl]amino}-L-alanine
  参考文献：
  名称：

  含有多氟烷基长链的非天然手性氨基酸化合物和其胺的酸盐、制备方法及用途

  摘要：

  本发明公开了多氟烷基长链非天然手性氨基酸、制备方法及其用途。具体而言，本发明提供一种含有多氟烷基长链的非天然手性氨基酸化合物(I)和其胺的酸盐；可用作氨基酸手性基元融合到多肽及蛋白质中，通过生物标记和分析来研究大分子动态生化过程。相对于天然手性氨基酸，制备的多氟烷基长链非天然手性氨基酸脂溶性高，生物相容性更好；制备的多氟烷基长链非天然手性氨基酸由于含有多氟官能团，引入多肽或蛋白质中，通过生物标记和分析来研究大分子动态生化过程。

  公开号：

  CN109956880B
• 作为产物：
  描述：

  2-(perfluoro-tert-butyloxy) ethyl tosylate 在 氨 作用下， 以 二乙二醇二甲醚 为溶剂， 40.0 ℃ 、1.3 MPa 条件下， 反应 24.0h， 以47%的产率得到2-[1,1-bis(trifluoromethyl)-2,2,2-trifluoroethoxy]ethyl amine
  参考文献：
  名称：

  氟化学中的新一代马尾辫：伯，仲和叔（九氟叔丁基丁氧基）乙胺的合成

  摘要：

  （Nonafluoro-叔-butyloxy）乙基甲苯磺酸酯4以65％的产率制备从nonafluoro-叔丁醇1使用市售试剂。4与HNR 1 R 2的进一步反应（R 1  = R 2  = H，CH 3 ; R 1  = H，R 2  = CH 3，（CH 2）3 C 8 F 17，CH 2 CH 2 OC（CF 3）3）提供适当的（CF 3）3种COCH 2 CH 2 NR 1 R 2胺，产率20-69％。的改进的总产率[（CF 3）3 COCH 2 CH 2 ] 3- Ñ NR Ñ至1由反应得到的（CF 3）3 CONA 2和（XCH 2 CH 2）3- Ñ NR Ñ（X = Cl，n  = 0，1，2，R = CH 3 ; X = CH 3 SO 2 O，n ＝ 1，R ＝ CH 3 SO 2）氮芥和类似的反应性β-取代的乙胺。标题胺是可流动的无色液体，在蒸汽中易挥发。庞大的氟马尾辫（CF

  DOI：

  10.1016/j.jfluchem.2006.06.020

文献信息

• ¹⁹F PARASHIFT Probes for Magnetic Resonance Detection of H₂O₂ and Peroxidase Activity
  作者：Meng Yu、Bailey S. Bouley、Da Xie、José S. Enriquez、Emily L. Que

  DOI：10.1021/jacs.8b05685

  日期：2018.8.22

  oxidative activity associated with inflammation using 19F magnetic resonance imaging (MRI). These agents display a large change in 19F chemical shift upon oxidation from Co(II) to Co(III), facilitating selective visualization of both species using chemical shift selective pulse sequences. This large chemical shift change is attributed to a large magnetic anisotropy in the high spin Co(II) complexes. Importantly

  活性氧和过氧化物酶表达水平升高通常与炎症和炎性疾病有关。我们开发了两种新型 Co(II) 复合物，可用于使用 19F 磁共振成像 (MRI) 检测与炎症相关的氧化活性。这些试剂在从 Co(II) 氧化为 Co(III) 时显示 19F 化学位移的巨大变化，使用化学位移选择性脉冲序列促进两种物质的选择性可视化。这种大的化学位移变化归因于高自旋 Co(II) 配合物中的大磁各向异性。重要的是，这两种试剂的不同反应性允许检测 H2O2 的产生和/或过氧化物酶的活性，
• Hypoxia-Responsive ¹⁹F MRI Probes with Improved Redox Properties and Biocompatibility
  作者：Da Xie、Seyong Kim、Vikraant Kohli、Arnab Banerjee、Meng Yu、José S. Enriquez、Jeffrey J. Luci、Emily L. Que

  DOI：10.1021/acs.inorgchem.7b00500

  日期：2017.6.5

  F-19 magnetic resonance imaging (MRI), an emerging modality in biomedical imaging, has shown promise for in vitro and in vivo preclinical studies. Here we present a It series of fluorinated Cu(II)ATSM derivatives for potential use as F-19 magnetic resonance agents for sensing cellular hypoxia. The synthesized complexes feature a hypoxia-targeting Cu2+ coordination core, nine equivalent fluorine atoms connected via a variable-length poly(ethylene glycol) linker. Introduction of the fluorine moiety maintains the planar coordination geometry of the,Cu2+ center, while the linker length modulates the Cu2+/+ reduction potential, F-19 NMR relaxation properties, and lipophilicity. In.particular, the F-19 NMI. relaxation properties were quantitatively evaluated by the Solomon-Bloembergen model, revealing a regular pattern of relaxation enhancement tuned by the distance between Cu2+ and F atoms. Finally, the potential utility of these complexes for sensing reductive environments was demonstrated using both F-19 MR phantom imaging and F-19 NMR, including experiments in intact live cells.
• FLUOROSURFACTANTS
  申请人：Claus Eckhard

  公开号：US20110088594A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds of the formulae (I), (II) and (III), to the use of compounds containing at least one perfluoro-tert-butoxy group and at least one substituted or unsubstituted aromatic end group as surface-active agent, and to a process for the preparation of compounds of the formula (II).
• [DE] FLUORTENSIDE<br/>[EN] FLUOROSURFACTANTS<br/>[FR] TENSIOACTIFS FLUORÉS
  申请人：MERCK PATENT GMBH

  公开号：WO2009149807A1

  公开（公告）日：2009-12-17

  Gegenstand der vorliegenden Erfindung sind Verbindungen der Formeln (I), (II) und (III), die Verwendung von Verbindungen enthaltend mindestens eine Perfluor-tert.-butoxy-Gruppe und mindestens eine substituierte oder unsubstituierte aromatische Endgruppe als oberflächenaktives Mittel und ein Verfahren zur Herstellung von Verbindungen der Formel (II).
• [EN] FLUORINATED POLY(LACTIC-CO-GLYCOLIC ACID) POLYMERS AND CORRESPONDING NANOPARTICLES AND DRUG ENCAPSULATED NANOPARTICLES<br/>[FR] POLYMÈRES POLY(ACIDE LACTIQUE-CO-GLYCOLIQUE) FLUORÉS ET NANOPARTICULES CORRESPONDANTES ET NANOPARTICULES ENCAPSULANT UN MÉDICAMENT
  申请人：SOLVAY SPECIALTY POLYMERS IT

  公开号：WO2019243477A1

  公开（公告）日：2019-12-26

  Described herein are fluorinated poly(lactic-co-glycolic acid) polymers ("PLGA"). Also described herein are fluorinated PLGA nanoparticles, drug encapsulated fluorinated PLGA nanoparticles, and corresponding dispersions. Relative to corresponding non-fluorinated PLGA nanoparticles, the fluorinated PLGA nanoparticles have desirable 19F nuclear magnetic resonance ("NMR") activities and concomitant relaxation times for use as 19F magnetic resonance imaging ("MRI") probes. It was surprisingly found that, for some fluorinated PLGA nanoparticle embodiments, the 19FNMR activity (and therefore the 19FMRI activity) could be tuned (e.g. turned on an off) by changing the pH of the nanoparticle dispersion. It was also surprisingly discovered that the 19FNMR activity could also be tuned by adjusting the relative concentration of the polar organic solvent to water in the formation medium, as described in detail below. Because the fluorinated PLGA nanoparticles include, by definition, fluorine, dmg loading and encapsulation efficiency is also significantly increased for fluorine containing drugs, relative to corresponding non-fluorinated PLGA.